News

Hosted on MSN11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - MSN
On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...
Hosted on MSN3mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...
Benzinga.com3mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease - Novartis (NYSE:NVS) - Benzinga
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.
MedCity News10mon
Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas
A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval, strengthening the product’s case to compete against two other ...
Nasdaq3mon
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
The approval Vanrafia marks the third drug approval for Novartis in its renal disease portfolio. Shares of Novartis have risen 16.5% year to date compared with the large cap pharmaceutical ...
Reuters11mon
US FDA approves Novartis' kidney disease drug | Reuters
US FDA approves Novartis' kidney disease drug. By Sriparna Roy. August 7, 2024 10:29 PM UTC Updated August 7, 2024. The logo of Swiss drugmaker Novartis is pictured at the ...
AOL11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - AOL
On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...
Nasdaq3mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication ... FDA Approves Novartis Drug for Rare Kidney Disease Treatment March 21, 2025 — 02:10 pm EDT.
Yahoo Finance11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - Yahoo Finance
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease. On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first ...
Yahoo Finance3mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease - Yahoo Finance
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) oral Fabhalta (iptacopan) for adults with C3 glomerulopathy (C3G) to reduce proteinuria (protein in the ...
Benzinga.com11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - Novartis (NYSE:NVS) - Benzinga
Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.